COMMENTARY

• Two Reasons MHLW Opposes Yearly NHI Price Revisions, “Annual” Dropped from Gov’t Policy Guidelines
  June 17, 2014

• Delicate Balancing Act Required for SGLT-2 Inhibitor Promotions - Safety vs Efficacy
  June 16, 2014

• Why Not Make RMPs for Existing Products as Differentiation Strategy?
  June 9, 2014

• 2013 Earnings Signal Foreign Drug Makers Losing Steam in Japan
  June 2, 2014

• Clinical Research Regulations at Crossroads: Guidelines or Legislation?
  May 26, 2014

• Was the Main Paper from VART Study “Practice” for a Grad Student?
  May 19, 2014

• Can CROs Become Independent Players? Compliance, Ethics Will Be Major Issues for Growing Industry
  April 28, 2014

• Industry Faces Tough Road to Institutionalization of Key Premium, Eligibility Up for Discussion
  April 21, 2014

• Approval of Novel Antiepileptic Drugs as Monotherapies Coming Closer to Reality
  April 7, 2014

• Will Japan NIH Initiative Create a “Japanese Model” that Overcomes Its Size Disadvantage?
  March 28, 2014

• CASE-J Flutter: Doesn’t Blopress Ad Overemphasize Its Benefits on Diabetes?
  March 19, 2014

• “Lack of Urgency” Leads to New Rule; Penalty for Low Price Settlement Rates May Have Been Inevitable
  March 12, 2014

• Hardships and Successes of Diversified Entrants Lead to Question: Will Pharmaceuticals Continue to Be a Growth Sector?
  March 5, 2014

• Revised JCS Guidelines Clarify Role of Novel Oral Anticoagulants in Patients with Atrial Fibrillation
  February 12, 2014

• Will JPWA’s Move to Integrate Tax Display Method Dispel Medical Institutions’ Misconception?
  January 31, 2014

• FY2014 May Be Year 1 of New Reform Era; Drug Makers Need to “Turn Calamity into Good Fortune”
  January 7, 2014

• First SGLT-2 Inhibitor Set to Debut Next April; Curtain Rising on “Unprecedentedly Competitive” Market
  December 18, 2013

• Bearing “Edo” in Its Name, Japan-Originated Edoxaban Set to Challenge Rival Anticoagulants in World Market
  December 6, 2013

• MHLW Shocks Generic Drug Industry by Proposing “50% Rule,” Expansion of Uniform Pricing
  November 19, 2013

• Range of Drugs Eligible for Premium for New Drug Development May Be Reviewed; Industry Needs to Dispel Suspicions
  November 13, 2013

ページ